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OBJECTIVES This study was done to determine the spillover and extraction of endothelin-1 (ET-1) in the
peripheral circulation, and to evaluate the factors that regulate local ET-1 extraction in the
peripheral circulation in patients with congestive heart failure (CHF).
BACKGROUND The relationship between the spillover and extraction of the ET-1 in the peripheral
circulation and systemic vascular resistance (SVR) has not been fully clarified.
METHODS We measured plasma levels of ET-1 both in femoral artery (FA) and femoral vein (FV) in 93
patients with CHF.
RESULTS Plasma ET-1 was significantly higher in FV than in FA in New York Heart Association
(NYHA) functional class II patients, but there was no difference of ET-1 between FA and
FV in functional class III patients. In patients with functional class IV, plasma ET-1 was
significantly lower in FV than in FA, and SVR was significantly higher than in patients with
NYHA class II or class III. Moreover, a significant positive correlation existed between
plasma ET-1 extraction across the lower leg and SVR in these patients. Among the various
neurohumoral factors and hemodynamics, plasma levels of ET-1, angiotensin II in the FA
showed an independent and significant relationship with the plasma arteriovenous difference
of ET-1 in the lower limb.
CONCLUSIONS Circulating ET-1 is extracted in peripheral circulation in patients with severe CHF,
suggesting the possibility of upregulation of ET receptors of vascular beds in the lower limb
in these patients. The peripheral extraction of ET-1 correlates with SVR in severe CHF
patients and is mainly regulated by the local ET-1 and renin angiotensin systems. (J Am Coll
Cardiol 1999;33:530–7) © 1999 by the American College of Cardiology
Previous studies have indicated that in many patients with
chronic congestive heart failure (CHF), an increase in
systemic vascular resistance (SVR) was associated with
increased levels of vasoconstrictive neurohumoral factors
including endothelin-1 (ET-1) (1), suggesting an important
role in the pathophysiology of CHF (2–9). The ET-1 is
produced and secreted by the endothelial cells of various
organs and acts as both a circulating hormone and a local
hormone involved in paracrine and autocrine systems. Al-
though previous reports including our study stated that the
main source of the increased ET-1 is pulmonary circulation
and local ET-1 production in the lung correlates with the
pulmonary vascular resistance in patients with CHF (5,6),
whether ET-1 is produced or extracted from the peripheral
vascular tissue and the relationship between the spillover
and extraction of the ET-1 in the peripheral circulation and
SVR in these patients remain unknown.
Numerous studies on the pharmacologic effects of ET-1
suggest that it plays an important pathophysiologic role in
systemic and pulmonary vasoconstriction (10–14). Recent
studies have shown that anti-ET-1 drugs decrease the
peripheral vascular resistance and blood pressure in both
normal subjects and in patients with CHF (15–17). More
recently, bosentan, an endothelin-receptor antagonist, sig-
nificantly lowered blood pressure in patients with hyperten-
sion (18), suggesting an important role for the local ET-1
system as an autocrine and paracrine factor in the regulation
of blood pressure and peripheral vascular resistance in
humans. Angiotensin II, norepinephrine, and ET-1 can
directly or indirectly increase ET-1 production from the
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vascular tissue (19–21), and these vasoconstrictors are in-
creased in the plasma in CHF, but the effects of these
endogenous vasoconstrictors on the local ET-1 spillover or
extraction remain unknown in CHF patients before and
after the treatments with angiotensin-converting enzyme
(ACE) inhibitors.
Although anti-ET-1 drugs decrease systemic vascular
resistance in patients with CHF (15,19), whether ET-1 is
produced or extracted in the peripheral vascular tissue in
humans remains unknown. Therefore, we examined the
spillover and extraction of the ET-1 in the lower limb
circulation and the relationship between the spillover and
extraction of the plasma ET-1 in the peripheral circulation
and SVR in patients with CHF, and we evaluated the
factors that regulate local ET-1 clearance in the peripheral
circulation.
METHODS
Patients. The subjects were 93 patients with symptomatic
left ventricular dysfunction without renal failure who un-
derwent cardiac catheterization for clinical indications. We
also selected 15 age-matched normal subjects who, admitted
complaining of chest pain, proved to be normal by coronary
angiography. Informed consent was obtained from all pa-
tients before participation in the study, and the protocol was
approved by the Human Investigations Committee of our
institution. The subjects were 69 men and 24 women
ranging in age from 17 to 79 years (mean: 59 years); 55
patients had suffered a myocardial infarction more than 3
months before the study, 25 had dilated cardiomyopathy,
and 10 had hypertensive heart disease. Forty-six patients
were classified according to the standards of the New York
Heart Association (NYHA) as functional class II, 23
patients as class III, and 24 patients as class IV. At the entry
of the study, 68 patients were treated with diuretics, 48 with
ACE inhibitors, 48 with digitalis, 65 with vasodilators, and
12 with beta-blockers. All drug treatments were discontin-
ued at least 12 h before start of the study. To evaluate the
effects of ACE inhibitors on the plasma levels of ET-1, 15
functional class IV patients underwent repeated right car-
diac catheterization more than 4 weeks after the study with
symptoms improved.
Study protocol. All patients were premedicated with an
oral dose of diazepam (5 mg) and rested in bed in the supine
position for at least 20 min. Right-sided cardiac catheter-
ization was performed using a 7F Swan-Ganz catheter. The
heart rate was monitored by electrocardiography. Blood
samples for measuring plasma ET-1 were collected simul-
taneously from the right femoral artery (FA) and femoral
vein (FV). Blood samples for measuring the plasma levels of
norepinephrine, angiotensin II, atrial natriuretic peptide
(ANP), and brain natriuretic peptide (BNP) were also
drawn from the right FA. A Swan-Ganz catheter was
inserted through the right FV into the main pulmonary
artery, where the pressure was measured. The catheter was
then advanced into the pulmonary artery, and the pulmo-
nary capillary wedge pressure was measured by inflating the
balloon. Cardiac output was determined by the thermodi-
lution method immediately after blood collection. Left
ventriculography was performed using contrast medium or a
radioisotope before or 1 week after the hemodynamic
measurements and blood sampling. To evaluate the effects
of ACE inhibitors on the plasma levels of ET-1, 15
functional class IV patients underwent repeated right car-
diac catheterization and blood samplings more than 4 weeks
after the study with symptoms improved.
Measurement of immunoreactive ET-1 and other vaso-
constrictor factors. Blood for the measurement of plasma
ET-1 levels was transferred to a chilled tube containing
EDTA (1 mg/ml) and aprotinin (500 kallikrein inactivator
units/ml), and then centrifuged at 3,000 rpm for 15 min at
4°C. The plasma thus obtained was stored at 230°C until
assayed. The ET-1 was extracted by mixing 2 ml of plasma
with 0.4 ml of 60% methanol containing 0.25 mg/ml
Preparative C18 (Waters Chromatography Division, Mit-
ford, Massachusetts). The recovery rate was calculated to be
72 6 3.9% (n 5 5) by 125I ET-1 with this method. The
plasma ET-1 level was determined using an antibody
directed against synthetic ET-1 (Peninsula Laboratories,
Belmont, California) and 125I ET-1 (Amersham Japan,
Tokyo) as previously reported (5). This antibody showed
100% cross-reactivity with ET-1, 7% with endothelin-2, 7%
with endothelin-3, and 17% with human big ET-1. How-
ever, it did not cross-react with angiotensin I or angiotensin
II, vasopressin, or human cardiac natriuretic peptides. The
minimum detectable level of ET-1 was 0.5 pg/tube, the
interassay coefficient of variation was 13% (n 5 10), and the
intraassay coefficient of variation was 11% (n 5 9).
Blood for measurement of the plasma levels of norepi-
nephrine and angiotensin II was transferred to a chilled tube
containing EDTA (1 mg/ml), centrifuged at 3,000 rpm for
15 min at 4°C, and the plasma thus obtained was stored at
230°C until assayed. Plasma norepinephrine concentration
was measured by high-performance liquid chromatography.
Plasma angiotensin II levels were measured by a radioim-
munoassay using a specific antibody directed against syn-
thetic angiotensin II (Special Research Laboratory, Tokyo,
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Japan) as previously reported (5). This antibody had 100%
cross-reactivity with angiotensin II, 0.3% cross-reactivity
with angiotensin I, and no cross-reactivity with ET-1,
vasopressin, and cardiac natriuretic peptides.
Samples for the assay of the plasma ANP and BNP
concentrations were transferred to chilled disposable tubes
containing aprotinin (500 kallikrein inactivator units/ml).
The blood samples were immediately placed on ice and
centrifuged at 4°C. Plasma ANP concentrations were mea-
sured with a specific immunoradiometric assay for a-human
ANP using a commercial kit (Shionoria, Japan) as previ-
ously reported (22).
Briefly, this assay uses two monoclonal antibodies against
a-human ANP, one recognizing a carboxyterminal se-
quence and the other the ring structure of ANP, and
measures a-human ANP by sandwiching it between the
two antibodies without plasma extraction. The minimal
detectable quantity of a-human ANP is 5 pg/ml. The
intraassay and interassay coefficients of variation were 5.1%
and 5.8%, respectively. This assay system did not cross-react
with angiotensin I or angiotensin II, vasopressin, or human
BNP. The cross-reactivity with human BNP was ,0.001%
on a molar basis.
Plasma BNP concentrations were measured with a spe-
cific immunoradiometric assay for human BNP using a
commercial kit (Shionoria, Japan) as previously reported
(22). Briefly, this assay uses two monoclonal antibodies
against human BNP, one recognizing a carboxyterminal
sequence and the other the ring structure of BNP, respec-
tively, and measures BNP by sandwiching it between the
two antibodies without plasma extraction. The minimal
detectable quantity of human BNP is 2 pg/ml. The intra-
assay and interassay coefficients of variation were 5.2% and
6.1%, respectively. This assay system did not cross-react
with angiotensin I or angiotensin II, vasopressin, or human
ANP. The cross-reactivity with human ANP was ,0.001%
on a molar basis.
Calculations. The mean arterial blood pressure and SVR
were calculated from standard formulas.
Statistical analysis. All results were expressed as the
mean 6 SEM. Comparisons between multiple groups were
determined by one-way analysis of variance (ANOVA) with
the Scheffe´ F test. Univariate and stepwise multivariate
linear regression analyses were used to detect independent
predictors of plasma ET-1 extraction in peripheral circula-
tion among the 18 variables (age, NYHA functional class,
heart rate, mean arterial blood pressure, cardiac index,
pulmonary capillary wedge pressure, left ventricular ejection
fraction, SVR, ANP, BNP, norepinephrine, ET-1, angio-
tensin II, and treatments such as diuretics, digitalis, angio-
tensin converting enzyme inhibitors, vasodilators, and beta-
blockers). Linear regression analysis was used to determine
the relationship between continuous variables. Statistical
analyses were done by use of a commercial computer
software package (StatView-J4.02: Abacus Concepts). A p
value ,0.05 was regarded as significant.
RESULTS
Hemodynamic data. Hemodynamic data are shown in
Table 1. The cardiac index and the left ventricular ejection
fraction were significantly lower in functional class IV
patients than in functional class II patients. In contrast,
pulmonary capillary wedge pressure increased with the
severity of functional class. The SVR was significantly
higher in functional class IV than in class II or class III
patients.
Neurohumoral data. Vasodilative cardiac natriuretic pep-
tides such as ANP and BNP increased with the severity of
functional class. Plasma norepinephrine was significantly
increased and angiotensin II was slightly increased in
functional class IV patients (see Table 2).
Plasma concentrations of ET-1 in the lower limb circu-
lation: Comparison with the severity of heart failure. In
normal subjects, plasma ET-1 significantly increased from
FA to FV (1.67 6 0.15 vs. 2.05 6 0.13, p 5 0.003). Figure
1 shows the plasma ET-1 levels in FA and FV in patients
with CHF. Plasma ET-1 levels significantly increased with
the severity of CHF. Plasma ET-1 significantly increased
from FA to FV (2.06 6 0.1 vs. 2.3 6 0.1 pg/ml, p 5 0.009)
in NYHA class II patients. There was no difference of ET-1
between FA and FV in functional class III patients. In
NYHA functional class IV patients, plasma ET-1 decreased
significantly from FA to FV (6.3 6 0.5 vs. 4.9 6 0.5 pg/ml,
p 5 0.0001).
Figure 2 shows the plasma ET-1 spillover in the lower
limb (ET-1 in FV 2ET-1 in FA) in normal subjects and in
patients with CHF. Plasma ET-1 spillover across the lower
Table 1. Hemodynamic Data
HR
(beats/min)
LVEF
(%)
MBP
(mm Hg)
MPA
(mm Hg)
PCWP
(mm Hg)
CI
(l/min/m2)
SVR
(dynezszcm25)
NYHA II (n 5 46) 72 6 1.8 36 6 1.1 87 6 2.2 13.7 6 0.4 7.2 6 0.5 2.8 6 0.1 1603 6 74
NYHA III (n 5 23) 84 6 4.5\ 32 6 2.4 89 6 3.9 20.3 6 2.1 12 6 1.2§ 2.6 6 0.1 1740 6 145
NYHA IV (n 5 24) 92 6 2.8‡ 30 6 2.2* 85 6 4.0 29.2 6 2.4‡** 20.9 6 1.5‡** 2.3 6 0.2* 2101 6 151†¶
*p , 0.05 vs. NYHA II. †p , 0.01 vs. NYHA II. ‡p , 0.001 vs. NYHA II. §p , 0.05 vs. NYHA II. \p , 0.01 vs. NYHA II. ¶p , 0.05 vs. NYHA III. **p , 0.001 vs. NYHA
III with ANOVA by the Scheffe´ F test.
CI 5 cardiac index; HR 5 heart rate; LVEF 5 left ventricular ejection fraction; MPA 5 mean pulmonary arterial pressure; PCWP 5 pulmonary capillary wedge pressure;
MBP 5 mean arterial blood pressure; SVR 5 systemic vascular resistance; NYHA 5 New York Heart Association.
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limb significantly decreased with the severity of CHF
(NYHA functional class II: 0.24 6 0.08; class III:
20.013 6 0.17; class IV: 21.4 6 0.3 pg/ml). There was a
significant negative correlation between the functional class
and the plasma ET-1 spillover in the lower limb (r 5
20.55, p , 0.0001).
Relationship between ET-1 extraction in the lower limb
and SVR in patients with CHF. No significant correlation
existed between plasma ET-1 or plasma ET-1 extraction in
the lower limb (ET-1 in FA 2 ET-1 in FV) and SVR in
patients with functional class II or class III. Although there
was no significant correlation between the plasma ET-1 in
FA and SVR, plasma ET-1 extraction in the lower limb
significantly correlated with SVR in functional class IV
patients (Fig. 3).
Relationship between plasma ET-1 extraction in the
lower limb circulation and clinical characteristics, treat-
ments, hemodynamics and neurohumoral factors. Table
3 shows the results of univariate and multivariate analyses to
assess the factors regulating the ET-1 extraction in lower
limb circulation in 93 patients with CHF. By univariate
analyses, 10 variables such as functional class, and neuro-
humoral and hemodynamic variables, were significant pre-
dictors of the plasma ET-1 extraction in the lower limb
circulation. According to stepwise multivariate analyses,
only high levels of the plasma arterial ET-1 (p , 0.0001),
angiotensin II (p 5 0.025) and SVR (p 5 0.0079) were
significant independent predictors of the plasma ET-1
extraction in the lower limb. Figure 4 shows the correlation
between the plasma levels of arterial ET-1 and the plasma
ET-1 extraction in the lower limb circulation by linear
regression analysis (r 5 0.705, p , 0.0001).
Plasma concentrations and extraction of ET-1 in the
peripheral circulation: Effects of ACE inhibitors. Figure
5 shows the plasma ET-1 levels in FA and FV before and
after administration of ACE inhibitors. Plasma ET-1 levels
decreased significantly from FA to FV in NYHA class IV
patients. After the treatment with ACE inhibitors, plasma
levels of ET-1 in both the FA and the FV significantly
decreased concomitant with the significant improvement of
symptoms. The plasma ET-1 extraction across the lower
limb significantly decreased (normalized) after treatment
with ACE inhibitors.
DISCUSSION
We demonstrated that local ET-1 spillover in the lower
limb occurred in normal subjects and in mild CHF patients
(NYHA functional class II) and ET-1 extraction was
predominant in patients with severe CHF (NYHA func-
tional class IV) concomitant with the significant increase of
SVR. Although plasma ET-1 levels increased in relation to
the severity of CHF as previously reported (2–5), the plasma
ET-1 spillover across the lower limb significantly decreased
with the severity of CHF in contrast to the significant
increase of the difference across the lung in the pulmonary
circulation as previously reported (data not shown) (5,6).
These findings indicate differential regulation of ET-1
spillover or extraction in the lung and the peripheral
circulation (such as the lower limb) in patients with CHF.
To our knowledge, the only report about arteriovenous
ET-1 extraction in patients with CHF was of renal extrac-
tion detected for the difference of plasma ET-1 between the
aorta and renal vein (23); however, the observation of those
investigators was partly due to the glomerular filtration of
ET-1. Therefore, we showed, for the first time, plasma
Figure 1. Plasma levels of endothelin-1 (ET-1) in age-matched
normal subjects and in patients with congestive heart failure. FA 5
femoral artery; FV 5 femoral vein. Closed columns represent the
ET-1 level in FA and open columns represent the ET-1 level in
FV. *p , 0.01, **p , 0.001 vs. the value of the ET-1 level in FA.
#p , 0.05 vs. the value of the ET-1 level of NYHA functional
class II patients. ##p , 0.0001 vs. the value of the ET-1 level of
NYHA functional class II or class III patients with ANOVA by
the Scheffe´ F test.
Table 2. Neurohumoral Data
ANP
(pg/ml)
BNP
(pg/ml)
Norepinephrine
(pg/ml)
Ang II
(pg/ml)
Plasma ET-1 Spillover in Leg
(pg/ml)
NYHA II (n 5 46) 81 6 9.4 134 6 20 284 6 35 25 6 5.4 0.24 6 0.08
NYHA III (n 5 23) 140 6 22 291 6 50 418 6 53 27 6 5.7 20.013 6 0.17
NYHA IV (n 5 24) 292 6 47*† 954 6 125*‡ 1192 6 240*† 53 6 18 21.34 6 0.3*‡
*p , 0.0001 vs. NYHA II. †p , 0.001 vs. NYHA III. ‡p , 0.0001 vs. NYHA III, with ANOVA by Scheffe´ F test.
ANP 5 atrial natriuretic peptide; BNP 5 brain natriuretic peptide; Ang II 5 angiotensin II; ET-1 5 endothelin-1; plasma ET-1 spillover in leg 5 ET-1 in femoral vein
2 ET-1 in femoral artery; NYHA 5 New York Heart Association.
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ET-1 was extracted in vascular beds in NYHA functional
class IV patients. Moreover, whether ET receptors are
upregulated or downregulated in CHF remains controver-
sial; our present study supports upregulation of ET recep-
tors in the vascular tissue of lower limb in patients with
severe CHF.
Previous studies, including one by Dupis et al. (24),
indicated that various organs rich in endothelial cells in-
cluding peripheral vascular tissue are also important sites for
clearance and production of ET-1 in patients with CHF, in
which ET-1 production is generally activated. The present
study suggests the balance of production and clearance in
the peripheral circulation differs with the severity of CHF.
Moreover, the ET-1 extraction in functional class IV
patients was normalized after the improvement of symp-
toms by ACE inhibitors. Indeed, Clavell et al. (25) recently
reported that the circulating and local ET-1 levels decreased
after treatment with ACE inhibitors in association with a
decrease in the systemic vascular resistance in a model of low
cardiac output CHF in dogs, suggesting the contribution of
the renin angiotensin system to the activation of the local
ET-1 production.
According to stepwise multivariate analyses, only high
levels of plasma arterial ET-1, angiotensin II and SVR were
significant independent predictors of the plasma ET-1
extraction in the lower limb circulation in the patients with
CHF, suggesting the local ET-1 extraction in peripheral
vascular tissue was mainly regulated by the local ET-1 and
renin angiotensin systems. These findings are consistent
with the role of local endogenous ET-1 in the peripheral
circulation in the pathophysiology of CHF. Because angio-
tensin II and ET-1 stimulate the ET-1 production in vitro
(19,20) and in vivo (21), the total amount of ET-1 produc-
tion in the peripheral vascular tissue may increase with the
severity of CHF.
Moreover, angiotensin II, which is increased in plasma of
CHF patients, induces upregulation of ET type A receptor as
well as its mRNA in human vascular smooth muscle cell in
vitro (26), and the findings of these investigators support our
data that plasma angiotensin II in FA independently correlated
with plasma arteriovenous ET-1 extraction in the lower circu-
lation, which may indicate upregulation of ET receptors.
Indeed, Schiffrin et al. (27) recently reported that the ET-1
mRNA was abundant in the small arteries of subcutaneous
gluteal fat in moderate to severe hypertensive patients, suggest-
ing that the amount of total ET-1 production in the lower
limb vascular tissue increases with the severity of CHF.
In the present study, the plasma venous ET-1 level
decreased relative to the arterial ET-1 level in the lower
limb in patients with severe CHF (NYHA class IV), in
which ET-1 production is generally activated at the tissue
level. Recently, Sakai et al. (28) reported that ET-1 receptor
antagonist improved long-term survival in rats with heart
failure in which the ET-A receptor was upregulated. These
findings suggest the local activity of ET-1 in the lower limb
vascular tissue is enhanced in patients with severe CHF.
This is attributed not only to the increase in the production
of ET-1 but also to the upregulation of ET-receptors.
Figure 2. Plasma endothelin-1 (ET-1) spillover in the leg in
age-matched normal subjects and in patients with congestive heart
failure. Plasma ET-1 spillover in the leg 5 ET-1 in femoral vein
2 ET-1 in femoral artery. *p , 0.0001 vs. the value of NYHA
class II. #p , 0.0001 vs. the value of NYHA class III with
ANOVA by the Scheffe´ F test.
Figure 3. Relationship between the plasma arterial endothelin-1 (ET-1) level and plasma ET-1 extraction in the lower limb and systemic
vascular resistance (SVR) in NYHA functional class IV patients. Plasma ET-1 extraction in the leg 5 ET-1 in femoral artery 2ET-1 in
femoral vein.
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These factors may contribute to the significant increase of
systemic vascular resistance in patients with NYHA class IV
owing to a significant positive correlation between plasma
ET-1 extraction in the peripheral circulation and SVR in
these patients (Fig. 3).
Because cardiac natriuretic peptides, which are in-
creased in CHF, have been reported to decrease the
angiotensin II-stimulated ET-1 production by endothe-
lial cells by increasing the level of second messenger,
cyclic guanosine monophosphate (20), we hypothesized
that the arterial levels of ANP and BNP modulate the
ET-1 spillover in patients with CHF. However, the
cardiac natriuretic peptide level did not independently
influence the plasma ET-1 extraction in the present
study, suggesting that the endogenous cardiac natriuretic
peptides are not the main factor regulating ET-1 secre-
tion in the lower limb circulation and the cardiac natri-
uretic peptide receptor coupled to guanylate cyclase may
be downregulated in the peripheral circulation in patients
with severe CHF as previously reported (22,29).
Clinical implications. Our findings indicate that the
plasma venous ET-1 level is underestimated compared to
the plasma arterial ET-1 level probably because of its
increased extraction in severe CHF. Moreover, the signifi-
cant extraction of ET-1 in the lower limb suggests the
possibility of upregulation of ET receptors in patients with
severe CHF (28), indicating the usefulness of ET receptor
antagonists in these patients.
Our present finding that the changes in the plasma levels
of ET-1 concomitant with the normalization of local ET-1
extraction before and after the treatments of ACE inhibitors
suggests an important local interaction between the renin
angiotensin system and endothelin system in patients with
CHF.
Patients with the highest plasma ET-1 levels during maxi-
mal exercise have been found to have the greatest reductions in
exercise capacity, perhaps by limiting exercise-induced vasodi-
lation (30,31); interestingly, the changes in plasma ET-1 levels
have been found to be a sensitive predictor of functional
parameters, such as NYHA functional class and 6-min walk
distance, after treatment with carvedilol, by which the mortal-
ity of patients with CHF was improved (32). Because the
ability of peripheral blood vessels to dilate in response to many
physiologic and pharmacologic vasodilator stimuli is markedly
attenuated in patients with CHF, a significant correlation
existed between the plasma ET-1 extraction in the lower limb
and NYHA functional class, suggesting the plasma ET-1
extraction contributes to exercise intolerance by limiting the
ability of the peripheral vasculature to dilate during exercise
(30,31). Further studies are needed to evaluate the relationship
between the plasma arteriovenous difference of ET-1 in the
lower limbs and the exercise tolerance in patients with CHF.
Study limitations. Blood samples were also collected from
the FA and FV to confirm the spillover or extraction of
ET-1 in the lower limb circulation. We measured the
plasma arteriovenous ET-1 difference, but this was not the
actual ET-1 production or clearance as it is influenced by
the balance of local production and clearance of ET-1 in the
lower limb. In addition, we measured the cardiac output,
but did not evaluate the blood flow in the lower limb.
However, a significant decrease of plasma ET-1 from FA to
FV in functional class IV patients is independent of the
Table 3. Univariate and Multivariate Linear Model of Plasma Endothelin-1 Extraction in the Lower Limb in Patients With CHF
Variable
Univariate
Corrrelation
Coefficient p-Value
Multivariate
Beta
Coefficient p-Value
Age (year) 0.073 NS
NYHA (functional class) 0.507 , 0.0001
Diuretics (treatment 5 1; no treatment 5 0) 0.158 NS
Digitalis (treatment 5 1; no treatment 5 0) 0.195 NS
ACEI (treatment 5 1; no treatment 5 0) 0.058 NS
Vasodilators (treatment 5 1; no treatment 5 0) 20.085 NS
b-blockers (treatment 5 1; no treatment 5 0) 20.05 NS
Heart rate (beats/min) 0.347 0.0006
Mean arterial blood pressure (mm Hg) 0.024 NS
Cardiac index (l/min/m2) 20.203 NS
Pulmonary capillary wedge pressure (mm Hg) 0.467 , 0.0001
Left ventricular ejection fraction (%) 20.219 0.0173
Systemic vascular resistance (dynezszcm25) 0.382 , 0.0001 0.00034 0.0079
Atrial natriuretic peptide (pg/ml) 0.529 , 0.0001
Brain natriuretic peptide (pg/ml) 0.459 , 0.0001
Norepinephrine (pg/ml) 0.508 , 0.0001
Endothelin-1 (pg/ml) 0.705 , 0.0001 0.302 , 0.0001
Angiotensin II (pg/ml) 0.382 0.0004 0.0036 0.025
After a stepwise multivariate linear regression analysis by the procedure of forward selection of variables (the F value for entering a variable into the model is 4.00), only three
variables as listed were selected and the other 15 variables were not selected.
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blood flow in the leg. It is difficult to evaluate the total
amount of production and clearance of ET-1 in the periph-
eral circulation of CHF patients, and further studies are
needed to clarify our hypothesis.
Conclusions. Local ET-1 spillover in the lower limb was
observed in normal subjects and in mild CHF patients.
However, circulating ET-1 is extracted in peripheral circu-
lation in patients with severe CHF, suggesting the possi-
bility of upregulation of ET receptors of vascular beds in the
lower limb in patients with severe CHF. The peripheral
extraction of ET-1 correlates with SVR in severe CHF
patients and is mainly regulated by the local ET-1 and renin
angiotensin systems in patients with CHF. Although the
physiologic and pathophysiologic role of the ET-1 extrac-
tion in the lower limb remains unclear, the significant
extraction of ET-1 in the lower limb suggests the possibility
of upregulation of ET receptors in patients with severe
CHF, indicating the usefulness of ET receptor antagonists
for vasodilation of the lower limb in patients with CHF.
Additional studies are needed to evaluate the relationship
between the improvement of blood flow in the lower limb
and the increase of exercise capacity in patients with CHF
after treatment with ET receptor antagonists.
Acknowledgments
We wish to thank Ms. Ikuko Sakaguchi for excellent
technical assistance. We also express thanks to Mr. Daniel
Mrozek for assistance in preparing the manuscript. This
study was supported by a Grant-in-Aid for Scientific
Research in Japan.
Reprint requests and correspondence: Takayoshi Tsutamoto,
MD, First Department of Internal Medicine, Shiga University of
Medical Science, Tsukinowa, Seta, Otsu 520-2192, Japan. E-mail:
tutamoto@belle.shiga-med.ac.jp.
REFERENCES
1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent
vasoconstrictor peptide produced by vascular endothelial cells.
Nature 1988;332:411–5.
2. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated
ET-1 in heart failure and loss of normal response to postural
change. Circulation 1992;85:510–7.
3. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma
endothelin correlates with extent of pulmonary hypertension
in patients with chronic congestive heart failure. Circulation
1992;85:504–9.
4. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M.
Relation between endothelin-1 spillover in the lungs and
pulmonary vascular resistance in patients with chronic heart
failure. J Am Coll Cardiol 1994;23:1427–33.
5. Yoshibayashi M, Hirata Y, Nakao K, et al. Plasma endothelin
concentrations in patients with pulmonary hypertension asso-
ciated with congestive heart defects: evidence of increased
production of endothelin in pulmonary hypertension. Circu-
lation 1991;84:2280–5.
6. Packer M. Neurohormonal interactions and adaptations in
congestive heart failure. Circulation 1988;77:721–9.
7. Francis GS, Goldsmith SR, Levine TB, Olivary MT, Cohn
JN. The neurohormonal axis in congestive heart failure. Ann
Intern Med 1984;101:370–7.
8. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepineph-
rine as a guide to prognosis in patients with chronic congestive
heart failure. N Engl J Med 1984;311:819–23.
9. Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of
plasma soluble intercellular adhesion molecule-1 and
endothelin-1 concentration in patients with chronic heart
failure. Am J Cardiol 1995;76:803–8.
10. Yanagisawa M, Inoue A, Ishikawa T, et al. Primary structure,
synthesis, and biological activity of rat endothelin, and
endothelium-derived vasoconstrictor peptide. Proc Natl Acad
Sci USA 1988;85:6964–7.
11. Miller WL, Redfield MM, Burnett JC Jr. Integrated cardiac,
renal, and endocrine actions of endothelin. J Clin Invest
1989;83:317–20.
12. Vierhapper H, Wagner O, Nowotny P, Waldhausl W. Effects
of ET-1 in man. Circulation 1990;81:1415–8.
13. Lerman A, Hildebrand FL, Aarhus LL, Burnett JC. Endo-
thelin has biological actions at pathophysiological concentra-
tions. Circulation 1991;83:1808–14.
14. Kiowski W, Luscher TF, Linder L, Buhler FR. Endothelin-
1-induced vasoconstriction in humans: reversal by calcium
Figure 4. Correlation between the plasma arterial endothelin-1
(ET-1) level and plasma ET-1 extraction in the peripheral
circulation in patients with congestive heart failure. Plasma ET-1
extraction in the peripheral circulation 5 ET-1 in femoral artery 2
ET-1 in femoral vein.
Figure 5. Plasma levels of endothelin-1 (ET-1) of femoral artery
(FA) and femoral vein (FV) and plasma ET-1 extraction in leg
before and after the treatments with angiotensin-converting en-
zyme inhibitors (ACEI). *p , 0.01 vs. the value of ET-1 in FA.
Plasma ET-1 extraction in the leg 5 ET-1 in femoral artery 2
ET-1 in femoral vein.
536 Tsutamoto et al. JACC Vol. 33, No. 2, 1999
ET-1 Extraction in Severe CHF February 1999:530–7
channel blockade but not by nitrovasodilators or endothelium-
derived relaxing factor. Circulation 1991;83:469–75.
15. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for
endothelin-1 mediated vasoconstriction in severe chronic
heart failure. Lancet 1995;346:732–6.
16. Haynes W, Ferro CJ, O’Kane KPJ, Somerville D, Lomax CC,
Webb DJ. Systemic endothelin receptor blockade decreases
peripheral vascular resistance and blood pressure in humans.
Circulation 1996;93:1860–70.
17. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJV.
Vasodilator effects of endothelin-converting enzyme inhibi-
tion and endothelin ETA receptor blockade in chronic heart
failure patients with ACE inhibitors. Circulation 1996;94:
2131–7.
18. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V,
for the Bosentan Hypertension Investigators. The effect of an
endothelin-receptor antagonists, bosentan, on blood pressure
in patients with essential hypertension. N Engl J Med 1998;
338:784–90.
19. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T,
Marumo F. Induction of endothelin-1 gene by angiotensin
and vasopressin in endothelial cells. Hypertension 1992;19:
753–7.
20. Kohno M, Yokokawa K, Horio T, Yasunari K, Murakawa K,
Takeda T. Atrial and brain natriuretic peptides inhibit the
endothelin-1 secretory response to angiotensin II in porcine
aorta. Circ Res 1992;70:241–7.
21. Jilma B, Krejcy K, Dirnberger E, et al. Effects of
angiotensin-II infusion at pressor and subpressor doses on
endothelin-1 plasma levels in healthy men. Life Sci 1997;60:
1859–66.
22. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of
compensation of endogenous cardiac natriuretic peptide sys-
tem in chronic heart failure: prognostic role of plasma brain
natriuretic peptide in patients with chronic symptomatic left
ventricular dysfunction. Circulation 1997;96:509–16.
23. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton J.
Plasma endothelin in chronic heart failure. Circulation 1992;
85:1374–9.
24. Dupis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmo-
nary circulation is an important site for both clearance and
production of endothelin-1. Circulation 1996;94:1578–84.
25. Clavell AL, Mattingly MT, Stevens TL, et al. Angiotensin-
converting enzyme inhibition modulates endogenous endo-
thelin in chronic canine thoracic inferior vena caval constric-
tion. J Clin Invest 1996;97:1286–92.
26. Hatakeyama H, Miyamori I, Yamagishi S, Takeda Y, Takeda
R, Yamamoto H. Angiotensin II up-regulates the expression
of type A endothelin receptor in human vascular smooth
muscle cells. Biochem Mol Biol Int 1994;34:127–34.
27. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced
expression of endothelin-1 gene in resistance arteries in
severe human essential hypertension. J Hypertens 1997;15:
57– 63.
28. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K,
Sugishita Y. Inhibition of myocardial endothelin pathway
improves long-term survival in heart failure. Nature 1996;384:
353–5.
29. Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y,
Yamaoka O, Kinoshita M. Possibility of downregulation of
atrial natriuretic peptide receptor coupled to guanylate cyclase
in peripheral vascular beds of patients with chronic severe
heart failure. Circulation 1993;87:70–5.
30. Krum H, Goldsmith R, Wilshire-Clement M, Miller M,
Packer M. Importance of endothelin in exercise intolerance of
heart failure. Am J Cardiol 1995;75:1282–3.
31. Krum H, Gu A, Wilshire-Clement M, et al. Changes in
plasma endothelin-1 levels reflect clinical response to
b-blocker in chronic heart failure. Am Heart J 1996;131:337–
41.
32. Packer M, Bristow MR, Cohn JN, et al. for the U.S.
Carvedilol Heart Failure Study Group. The effect of carvedilol
on morbidity and mortality in patients with chronic heart
failure. N Engl J Med 1996;334:1349–55.
537JACC Vol. 33, No. 2, 1999 Tsutamoto et al.
February 1999:530–7 ET-1 Extraction in Severe CHF
